Antineoplastics

Antineoplastics

Agents that inhibit or prevent the development, maturation, and proliferation of malignant cells.
References in periodicals archive ?
The guide omits interactions involving anesthesia, the specialist use of multiple antiretrovirals and multiple antineoplastics or intravenous antineoplastics, and non-interactions.
Also, our study's definition of exposure was broad: in addition to those directly contacting antineoplastics during their preparation, administration, and cleanup, we counted workers with potential for contact with contaminated work surfaces.
Other new antineoplastics are the antiandrogen enzalutamide (Xtandi; prostate cancer but could be used for other cancers), the proteasome inhibitor carfilzomib (Kyprolis; multiple myeloma), and the protein synthesis inhibitor omacetaxine (Synribo; leukemia).
Interactions involving anesthesia, the specialist use of multiple antiretrovirals, the specialist use of multiple antineoplastics or intravenous antineoplastics, and non-interactions are mostly omitted.
The Occupational Safety and Health Administration (OSHA) and the Environmental Protection Agency (EPA) are regulatory agencies that establish regulations regarding the management of antineoplastics that must be obeyed by law.
Largely used to treat cancer, antineoplastics represented the fourth-leading specialty-drug therapy class in 2005.
But antineoplastics would be best prescribed on "a fixeddose-per-adult basis unless our scientific studies show otherwise.
In addition to the drugs noted above, the list includes antineoplastics, beta-blockers, bronchodilators, lipid regulators, hypnotics, antibiotics, antiseptics, X-ray contrast agents, sunscreen agents, caffeine, and fragrances such as synthetic musks.
The Czech Republic pharmaceutical market is dominated by the sales of antineoplastics and cardiovascular drugs.
The global cancer market is becoming increasingly competitive, with two therapeutic classes, namely antineoplastics and cytostatic hormonal treatments, dominating this sector.
However, current adjuvant therapeutics like antineoplastic agents and immunomodulators have low efficacy ratings and high toxicity levels, prompting a pressing need for novel treatments with improved response rates and safety profiles.